Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

THIOTEPA for Diffuse large b-cell lymphoma refractory: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 5 adverse event reports in the FDA FAERS database where THIOTEPA was used for Diffuse large b-cell lymphoma refractory.

Most Reported Side Effects for THIOTEPA

Side Effect Reports % Deaths Hosp.
Off label use 762 11.2% 187 142
Febrile neutropenia 645 9.4% 89 144
Mucosal inflammation 616 9.0% 93 131
Cytomegalovirus infection 446 6.5% 87 48
Product use in unapproved indication 425 6.2% 86 63
Pyrexia 359 5.3% 74 147
Drug ineffective 358 5.2% 77 101
Acute graft versus host disease in skin 355 5.2% 70 51
Acute graft versus host disease 331 4.8% 98 36
Cytomegalovirus infection reactivation 325 4.8% 57 56
Infection 318 4.7% 218 7
Venoocclusive liver disease 306 4.5% 115 59
Thrombocytopenia 297 4.3% 47 65
Neutropenia 288 4.2% 79 44
Sepsis 271 4.0% 138 53

Other Indications for THIOTEPA

Bone marrow conditioning regimen (1,551) Allogenic stem cell transplantation (1,476) Stem cell transplant (799) Central nervous system lymphoma (396) Diffuse large b-cell lymphoma (335) Autologous haematopoietic stem cell transplant (275) Product used for unknown indication (258) Prophylaxis against transplant rejection (195) Medulloblastoma (184) Chemotherapy (181)

Other Drugs Used for Diffuse large b-cell lymphoma refractory

RITUXIMAB (667) EPCORITAMAB-BYSP (353) AXICABTAGENE CILOLEUCEL (336) BENDAMUSTINE (283) CYCLOPHOSPHAMIDE (226) POLATUZUMAB VEDOTIN (223) ETOPOSIDE (165) POLATUZUMAB VEDOTIN-PIIQ (158) GEMCITABINE (147) LENALIDOMIDE (143)

Related Pages

THIOTEPA Full Profile All Diffuse large b-cell lymphoma refractory Drugs THIOTEPA Demographics THIOTEPA Timeline